Immuneering (NASDAQ:IMRX) Stock Rating Lowered by Wall Street Zen

Immuneering (NASDAQ:IMRX) was downgraded by research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report issued on Saturday.

A number of other brokerages have also recently weighed in on IMRX. Needham & Company LLC restated a “buy” rating and set a $11.00 price objective on shares of Immuneering in a research note on Monday, March 9th. Weiss Ratings reissued a “sell (d-)” rating on shares of Immuneering in a research report on Friday, March 27th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $16.50.

Immuneering Stock Performance

Shares of IMRX opened at $5.52 on Friday. The company has a 50 day moving average price of $5.12 and a 200-day moving average price of $5.87. Immuneering has a fifty-two week low of $1.10 and a fifty-two week high of $10.08. The stock has a market capitalization of $356.87 million, a PE ratio of -4.00 and a beta of 0.43.

Immuneering (NASDAQ:IMRX) last announced its quarterly earnings results on Friday, March 6th. The company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.31) by $0.13. Equities research analysts forecast that Immuneering will post -1.86 EPS for the current year.

Insiders Place Their Bets

In related news, Director Thomas J. Schall purchased 21,645 shares of the firm’s stock in a transaction on Thursday, January 15th. The stock was acquired at an average price of $4.67 per share, with a total value of $101,082.15. Following the completion of the acquisition, the director owned 74,530 shares in the company, valued at approximately $348,055.10. This represents a 40.93% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Peter Feinberg acquired 20,000 shares of Immuneering stock in a transaction dated Monday, January 12th. The stock was purchased at an average price of $4.35 per share, with a total value of $87,000.00. Following the completion of the purchase, the director owned 135,441 shares of the company’s stock, valued at approximately $589,168.35. The trade was a 17.32% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last ninety days, insiders acquired 51,819 shares of company stock valued at $234,472. Corporate insiders own 22.90% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in IMRX. Sanofi purchased a new position in shares of Immuneering during the third quarter worth $18,960,000. Empery Asset Management LP purchased a new position in Immuneering during the fourth quarter valued at approximately $17,601,000. State Street Corp raised its position in Immuneering by 1,289.7% during the fourth quarter. State Street Corp now owns 2,402,238 shares of the company’s stock valued at $15,807,000 after acquiring an additional 2,229,374 shares in the last quarter. Vanguard Group Inc. raised its position in Immuneering by 128.5% during the third quarter. Vanguard Group Inc. now owns 2,415,244 shares of the company’s stock valued at $16,907,000 after acquiring an additional 1,358,322 shares in the last quarter. Finally, Citadel Advisors LLC purchased a new position in Immuneering during the third quarter valued at approximately $6,602,000. Hedge funds and other institutional investors own 67.65% of the company’s stock.

About Immuneering

Immuneering (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering’s machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company’s AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company’s lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.